- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 | 1 | GlobeNewswire (USA) | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.09. | Gain Therapeutics extends Phase 1b Parkinson's treatment study | 1 | Investing.com | ||
| 18.09. | Gain Therapeutics, Inc.: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease | 94 | GlobeNewswire (Europe) | Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled... ► Artikel lesen | |
| 25.08. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target | 2 | Investing.com | ||
| 25.08. | BTIG lowers Gain Therapeutics stock price target to $9 on biomarker data timing | 2 | Investing.com | ||
| 12.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Gain Therapeutics GAAP EPS of -$0.19 misses by $0.02 | 1 | Seeking Alpha | ||
| 17.07. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Pricing of $7.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 15.07. | Gain Therapeutics stock falls after announcing public offering | 2 | Investing.com | ||
| 15.07. | Gain Therapeutics announces proposed public offering | 1 | Seeking Alpha | ||
| 15.07. | Gain Therapeutics-Aktie fällt nach Ankündigung einer Kapitalerhöhung | 3 | Investing.com Deutsch | ||
| 15.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 03.07. | Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations | 1 | Investing.com | ||
| 30.06. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation | 100 | GlobeNewswire (Europe) | As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid... ► Artikel lesen | |
| 24.06. | Gain Therapeutics erhöht genehmigte Stammaktien nach Aktionärsabstimmung auf 100 Millionen | 1 | Investing.com Deutsch | ||
| 24.06. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting | 2 | GlobeNewswire (USA) | ||
| 28.05. | Gain Therapeutics announces $100M mixed shelf offering | 1 | Seeking Alpha | ||
| 14.05. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update | 251 | GlobeNewswire (Europe) | BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
| QIAGEN | 39,470 | +0,71 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,612 | +4,36 % | Von Abnehmspritzen bis Krebstherapie: Diese Plattform-Technologie greift gleich mehrere Milliardenmärkte an! | Anzeige / WerbungDie moderne Medizin steht vor einer gewaltigen Aufgabe: Immer mehr Menschen leiden an sogenannten Wohlstandserkrankungen wie Adipositas, Diabetes, Multiple Sklerose oder MASH, der gefürchteten... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| BIONTECH | 89,10 | -0,11 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,620 | +2,23 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
| APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |
GAIN THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.